NEW YORK ( TheStreet) -- The evolution of diabetes treatment will continue to improve as the years go on. TheStreet's Jill Malandrino is with Nadav Kidron, CEO of Oramed Pharmaceuticals (ORMP), to discuss the company's new treatment.
[video] Quick Take: Revolutionizing Diabetes Treatment
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts